Hyperinflation is a cardinal feature of COPD associated with reduced daily physical activity and increased mortality.
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Although bronchodilators and pulmonary rehabilitation have some effect many patients with COPD remain highly symptomatic.
The most established treatment is lung volume reduction surgery and results from the NETT trial show improved survival in appropriately selected patients with upper lobe predominant disease and low exercise capacity which are sustained out to at least 7 years. There is a Grade A evidence for LVRS in ARTS/ERS COPD guidelines and patients should be being systematically assessed for potential suitability. The risk of adverse outcomes in modern practice appears to be less than in the NETT. 7 The cost/QALY of LVRS is between $40,0000 and $50,000. Airway bypass techniques should work in the presence of collateral ventilation but are limited by problems keeping them patent, so benefit is very short-lived.
As the evidence base and experience with patient selection for different therapies develops it is important for patients with potentially treatable emphysema to be discussed in a multidisciplinary meeting including chest physicians, radiologists and surgeons.
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